前列腺癌特异性膜抗原用于前列腺癌的诊断与治疗研究进展
Progress in the Diagnosis and Treatment of Prostate Cancer Specific Membrane Antigen for Prostate Cancer
DOI: 10.12677/ACM.2019.95106, PDF,   
作者: 沈洪君：重庆市渝北区人民医院泌尿外科，重庆
关键词: 前列腺特异性膜抗原；前列腺癌；Prostate Specific Membrane； Prostate Cancer
摘要: 前列腺特异性膜抗原(Prostate specific membrane, PSMA)是具有叶酸水解酶和羧肽酶的2型整合膜糖蛋白，具有较高的前列腺组织特异性，其在低分化及转移性前列腺癌中呈现高表达，与前列腺肿瘤恶性程度正相关，基于此，以PSMA为靶标检查及治疗前列腺癌的影像学方式不断发展。该文章目的在于回顾PSMA作为前列腺癌影像学诊断和治疗标志物的研究进展。
Abstract: Prostate specific membrane (PSMA) is a type 2 integral membrane glycoprotein with folate hy-drolase and carboxypeptidase, which has high prostate tissue specificity and is high in poorly dif-ferentiated and metastatic prostate cancer. The expression is positively correlated with the degree of malignancy of prostate tumors. Based on this, the imaging method for detecting and treating prostate cancer with PSMA is continuously developed. The aim of this article is to review the progress of PSMA as a marker for imaging diagnosis and treatment of prostate cancer.
文章引用：沈洪君. 前列腺癌特异性膜抗原用于前列腺癌的诊断与治疗研究进展[J]. 临床医学进展, 2019, 9(5): 697-702. https://doi.org/10.12677/ACM.2019.95106

参考文献

[1] Horoszewicz, J.S., Kawinski, E. and Murphy, G.P. (1987) Monoclonal Antibodies to a New Antigenic Marker in Epi-thelial Prostatic Cells and Serum of Prostatic Cancer Patients. Anticancer Research, 7, 927-935.
[2] Ghosh, A. and Heston, W.D.W. (2004) Tumor Target Prostate Specific Membrane Antigen (PSMA) and Its Regulation in Prostate Cancer. Journal of Cellular Biochemistry, 91, 528-539. [Google Scholar] [CrossRef] [PubMed]
[3] Chang, S.S., Gaudin, P.B., Reuter, V.E. and Heston, W.D.W. (2000) Prostate-Specific Membrane Antigen: Present and Future Applications. Urology, 55, 622-629. [Google Scholar] [CrossRef] 
[4] Yao, V. and Bacich, D.J. (2006) Prostate Specific Membrane Antigen (PSMA) Expression Gives Prostate Cancer Cells a Growth Advantage in a Physiologically Relevant Folate Environment in Vitro. The Prostate, 66, 867-875. [Google Scholar] [CrossRef] [PubMed]
[5] Yao, V., Berkman, C.E., Choi, J.K., O’Keefe, D.S. and Bacich, D.J. (2010) Expression of Prostate-Specific Membrane Antigen (PSMA), Increases Cell Folate Uptake and Proliferation and Suggests a Novel Role for PSMA in the Uptake of the Non-Polyglutamated Folate, Folicacid. The Prostate, 70, 305-316. [Google Scholar] [CrossRef] [PubMed]
[6] Zhang, Y., Guo, Z., Du, T., Chen, J., Wang, W., Xu, K., et al. (2013) Prostate Specific Membrane Antigen (PSMA): A Novel Modulator of p38 for Proliferation, Migration, and Survival in Prostate Cancer Cells. The Prostate, 73, 835-841. [Google Scholar] [CrossRef] [PubMed]
[7] Guo, Z., Lai, Y., Du, T., Zhang, Y., Chen, J., Bi, L., et al. (2014) Prostate Specific Membrane Antigen Knockdown Impairs the Tumorigenicity of LNCaP Prostate Cancer Cells by Inhibiting the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway. Chinese Medical Journal, 127, 929-936.
[8] Xu, L., Wang, Z., Li, X.-F., He, X., Guan, L.-L., Tuo, J.-L., et al. (2013) Screening and Identification of Significant Genes Related to Tumor Metastasis and PSMA in Prostate Cancer Using Microarray Analysis. Oncology Reports, 30, 1920-1928. [Google Scholar] [CrossRef] [PubMed]
[9] Miyahira, A.K., Pienta, K.J., Morris, M.J., Bander, N.H., Baum, R.P., Fendler, W.P., et al. (2018) Meeting Report from the Prostate Cancer Foundation PSMA-Directed Radionuclide Scien-tific Working Group. The Prostate, 78, 775-789. [Google Scholar] [CrossRef] [PubMed]
[10] Fanti, S., Minozzi, S., Antoch, G., Banks, I., Briganti, A., Carrio, I., et al. (2018) Consensus on Molecular Imaging and Theranostics in Prostate Cancer. The Lancet Oncology, 19, e696-e708. [Google Scholar] [CrossRef] 
[11] Fendler, W.P., Schmidt, D.F., Wenter, V., Thierfelder, K.M., Zach, C., Stief, C., et al. (2016) 68GaPSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. Journal of Nuclear Medicine, 57, 1720-1725. [Google Scholar] [CrossRef] [PubMed]
[12] Woythal, N., Arsenic, R., Kempkensteffen, C., Miller, K., Janssen, J.C., Huang, K., et al. (2018) Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer. Journal of Nuclear Medicine, 59, 238-243. [Google Scholar] [CrossRef] [PubMed]
[13] Uprimny, C., Kroiss, A.S., Decristoforo, C., Fritz, J., von Gug-genberg, E., Kendler, D., et al. (2017) 68Ga-PSMA-11 PET/CT in Primary Staging of Prostate Cancer: PSA and Gleason Score Predict the Intensity of Tracer Accumulation in the Primary Tumour. European Journal of Nuclear Medicine and Molecular Imaging, 44, 941-949. [Google Scholar] [CrossRef] [PubMed]
[14] Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M.G., De Santis, M., et al. (2017) EAU-ESTROSIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 71, 618-629. [Google Scholar] [CrossRef] [PubMed]
[15] van Leeuwen, P.J., Emmett, L., Ho, B., Delprado, W., Ting, F., Nguyen, Q. and Stricker, P.D. (2017) Prospective Evaluation of 68Gallium-Prostate-Specific Membrane Antigen Posi-tron Emission Tomography/Computed Tomography for Preoperative Lymph Node Staging in Prostate Cancer. Uro-logical Oncology, 119, 209-215. [Google Scholar] [CrossRef] [PubMed]
[16] Gorin, M.A., Rowe, S.P., Patel, H.D., Vidal, I., Mana-Ay, M., Javadi, M.S., et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. Journal of Urology, 199, 126-132. [Google Scholar] [CrossRef] [PubMed]
[17] Maurer, T., Gschwend, J.E., Rauscher, I., Souvatzoglou, M., Haller, B., Weirich, G., et al. (2016) Diagnostic Efficacy of 68Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. Journal of Urology, 195, 1436-1443. [Google Scholar] [CrossRef] [PubMed]
[18] Ireson, C.R. and Kelland, L.R. (2006) Discovery and Development of Anticancer Aptamers. Molecular Cancer Therapeutics, 5, 2957-2962. [Google Scholar] [CrossRef] 
[19] Lupold, S.E., Hicke, B.J., Lin, Y. and Coffey, D.S. (2002) Identification and Characterization of Nuclease-Stabilized RNA Molecules that Bind Human Prostate Cancer Cells via the Prostate-Specific Membrane Antigen. Cancer Research, 62, 4029-4033.
[20] Xu, W., Siddiqui, I.A., Nihal, M., Pilla, S., Rosenthal, K., Mukhtar, H., et al. (2013) Aptamer-Conjugated and Doxorubicin-Loaded Unimolecular Micelles for Targeted Therapy of Prostate Cancer. Biomaterials, 34, 5244-5253. [Google Scholar] [CrossRef] [PubMed]
[21] Wang, X., Ma, D., Olson, W.C. and Heston, W.D.W. (2011) In Vitro and in Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Anti-body to Prostate-Specific Membrane Antigen. Molecular Cancer Therapeutics, 10, 1728-1739. [Google Scholar] [CrossRef] 
[22] Petrylak, D.P., Smith, D.C., Appleman, L.J., Fleming, M.T., Hussain, A., Dreicer, R., et al. (2014) A Phase 2 Trial of Prostate-Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Taxane-Refractory Metastatic Castration-Resistant Prostate Cancer (mCRPC). Journal of Clinical Oncology, 32, 5023-5023. [Google Scholar] [CrossRef] 
[23] Denmeade, S.R., Mhaka, A.M., Rosen, D.M., Brennen, W.N., Dalrymple, S., Dach, I., et al. (2012) Engineering a Prostate-Specific Membrane Antigen-Activated Tumor En-dothelial Cell Prodrug for Cancer Therapy. Science Translational Medicine, 4, 140ra86. [Google Scholar] [CrossRef] [PubMed]
[24] Ma, Q., Safar, M., Holmes, E., Wang, Y., Boynton, A.L. and Junghans, R.P. (2004) Anti-Prostate Specific Membrane Antigen Designer T Cells for Prostate Cancer Therapy. The Prostate, 61, 12-25. [Google Scholar] [CrossRef] [PubMed]
[25] Sugimoto, Y., Hirota, M., Yoshikawa, K., Sumitomo, M., Nakamura, K., Ueda, R., et al. (2014) The Therapeutic Potential of a Novel PSMA Antibody and Its IL-2 Conjugate in Prostate Cancer. Anticancer Research, 34, 89-97.
[26] Yeku, O. and Slovin, S.F. (2016) Immune Therapy for Prostate Cancer. The Cancer Journal, 22, 334-341. [Google Scholar] [CrossRef] 
[27] Bandekar, A., Zhu, C., Jindal, R., Bruchertseifer, F., Mor-genstern, A. and Sofou, S. (2014) Anti-Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Poten-tial Targeted Antivascular α-Particle Therapy of Cancer. Journal of Nuclear Medicine, 55, 107-114. [Google Scholar] [CrossRef] [PubMed]

为你推荐